Skip to main content

Thyroid Cancer Benefits the Prognosis of Ovarian Cancer: A SEER-Based Study

Abstract

Introduction

To explore the effect of a second thyroid cancer (TC) on ovarian cancer (OC) patient survival, we compared OC patients with or without a second primary TC using data from the Surveillance, Epidemiology, and End Results (SEER) database.

Methods

Data for OC only, female TC only and OC patients with a second TC (OC2TC) from two periods, 2000–2014 and 1980–1994, were extracted from the SEER database. Differences in clinicopathological and treatment characteristics were analysed using the chi-square test. Cox regression analyses were used to identify risk factors associated with OC survival. Disease-specific survival (DSS) and overall survival (OS) curves were compared using the log-rank test.

Results

There were 109 OC2TC patients from 2000 to 2014, and significant differences (P < 0.001) in the mean age at OC diagnosis, TNM stage and surgical history were found between OC and OC2TC patients. Several factors, including age, grade, TNM stage, histological type and surgical history, influenced OC survival (P < 0.001). OC2TC patients showed better survival than OC patients from 2000 to 2014, regardless of age, TNM stage or surgical history. However, this superiority was not significant in cases from 1980 to 1994 (P = 0.222 for OS).

Conclusion

Survival was better with OC2TC than with OC from 2000 to 2014 rather than 1980–1994, suggesting that TC improved the survival of OC patients from 2000 to 2014.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. https://doi.org/10.3322/caac.21387.

    Article  Google Scholar 

  2. 2.

    Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics review, 1975–2014, based on November 2016 SEER data submission, posted to the SEER web site, April 2017. MD: National Cancer Institute Bethesda; 2017.

    Google Scholar 

  3. 3.

    NCCN. National Comprehensive Cancer Network (NCCN) guidelines for OC, version 4.2017. 2017. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed 9 Nov 2017.

  4. 4.

    Choi JH, Wong AS, Huang HF, Leung PC. Gonadotropins and ovarian cancer. Endocr Rev. 2007;28(4):440–61. https://doi.org/10.1210/er.2006-0036.

    Article  CAS  PubMed  Google Scholar 

  5. 5.

    Jonsson JM, Skovbjerg Arildsen N, Malander S, et al. Sex steroid hormone receptor expression affects ovarian cancer survival. Transl Oncol. 2015;8(5):424–33. https://doi.org/10.1016/j.tranon.2015.09.002.

    Article  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Zhao D, Zhang F, Zhang W, He J, Zhao Y, Sun J. Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2013;23(1):25–33. https://doi.org/10.1097/IGC.0b013e3182788466.

    Article  PubMed  Google Scholar 

  7. 7.

    Shi LF, Wu Y, Li CY. Hormone therapy and risk of ovarian cancer in postmenopausal women: a systematic review and meta-analysis. Menopause. 2016;23(4):417–24. https://doi.org/10.1097/GME.0000000000000550.

    Article  PubMed  Google Scholar 

  8. 8.

    Minlikeeva AN, Freudenheim JL, Cannioto RA, et al. History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. Br J Cancer. 2017;117(7):1063–9. https://doi.org/10.1038/bjc.2017.267.

    Article  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Journy NMY, Bernier MO, Doody MM, Alexander BH, Linet MS, Kitahara CM. Hyperthyroidism, hypothyroidism, and cause-specific mortality in a large cohort of women. Thyroid. 2017;27(8):1001–100. https://doi.org/10.1089/thy.2017.0063.

    Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Agarwal R, Kaye SB. Prognostic factors in ovarian cancer: how close are we to a complete picture? Ann Oncol. 2005;16(1):4–6. https://doi.org/10.1093/annonc/mdi104.

    Article  CAS  PubMed  Google Scholar 

  11. 11.

    Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JF. A prognostic model for ovarian cancer. Br J Cancer. 2001;85(7):944–52. https://doi.org/10.1038/sj.bjc.6692030.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Hsieh MT, Wang LM, Changou CA, et al. Crosstalk between integrin alphavbeta3 and ERalpha contributes to thyroid hormone-induced proliferation of ovarian cancer cells. Oncotarget. 2017;8(15):24237-49. https://doi.org/10.18632/oncotarget.10757.

    Article  PubMed  Google Scholar 

  13. 13.

    Shinderman-Maman E, Cohen K, Weingarten C, et al. The thyroid hormone-alphavbeta3 integrin axis in ovarian cancer: regulation of gene transcription and MAPK-dependent proliferation. Oncogene. 2016;35(15):1977–87. https://doi.org/10.1038/onc.2015.262.

    Article  CAS  PubMed  Google Scholar 

  14. 14.

    Shinderman-Maman E, Cohen K, Moskovich D, et al. Thyroid hormones derivatives reduce proliferation and induce cell death and DNA damage in ovarian cancer. Sci Rep. 2017;7(1):16475. https://doi.org/10.1038/s41598-017-16593-x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Shinderman-Maman E, Weingarten C, Moskovich D, et al. Molecular insights into the transcriptional regulatory role of thyroid hormones in ovarian cancer. Mol Carcinog. 2017. https://doi.org/10.1002/mc.22735.

    Article  PubMed  Google Scholar 

  16. 16.

    Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418–28.

    Article  CAS  PubMed  Google Scholar 

  17. 17.

    Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer American Thyroid Association. Arch Intern Med. 1996;156(19):2165–72.

    Article  CAS  PubMed  Google Scholar 

  18. 18.

    Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16(2):109–42. https://doi.org/10.1089/thy.2006.16.109.

    Article  PubMed  Google Scholar 

  19. 19.

    American Thyroid Association Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-214. https://doi.org/10.1089/thy.2009.0110.

    Article  Google Scholar 

  20. 20.

    Silva EG, Tornos C, Malpica A, Deavers MT, Tortolero-Luna G, Gershenson DM. The association of benign and malignant ovarian adenofibromas with breast cancer and thyroid disorders. Int J Surg Pathol. 2002;10(1):33–9. https://doi.org/10.1177/106689690201000106.

    Article  PubMed  Google Scholar 

  21. 21.

    Carrera MP, Ramirez-Exposito MJ, Valenzuela MT, et al. Pyrrolidon carboxypeptidase activities in the hypothalamus–pituitary–thyroid and hypothalamus–pituitary–ovary axes of rats with mammary gland cancer induced by N-methyl nitrosourea. Horm Metab Res. 2005;37(2):74-8. https://doi.org/10.1055/s-2005-861158.

    Article  CAS  Google Scholar 

  22. 22.

    Schneider G, Kopach K, Ohanian H, Bonnefond V, Mittler JC, Ertel NH. The hypothalamic-pituitary-gonadal axis during hyperthyroidism in the rat. Endocrinology. 1979;105(3):674–9. https://doi.org/10.1210/endo-105-3-674.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Funding

This study was funded by the Natural Science Foundation of Zhejiang Province of China (grant numbers LY13H160039 and LY18H160039) and the Traditional Chinese Medicine Science and Technology Project of Zhejiang Province of China (grant number C-2013-W209). The sponsors also partially funded the article processing charges.

Editorial Assistance

This manuscript was edited for proper English language, grammar, punctuation, spelling, and overall style by one or more of the highly qualified native English-speaking editors at American Journal Experts.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosures

Qiong Yang, Zhiyong Wu, Xujun He, Leibo Yu, Xiaofei Zhang and Kefeng Lei have nothing to disclose.

Compliance with Ethics Guidelines

All SEER data were accessed with approval from the SEER database and, as such, this article does not contain any studies with human participants or animals performed by any of the authors.

Data Availability

The datasets analysed during the current study are available from the corresponding author on reasonable request.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Kefeng Lei.

Additional information

Enhanced Digital Features

To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.7751924.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yang, Q., Wu, Z., He, X. et al. Thyroid Cancer Benefits the Prognosis of Ovarian Cancer: A SEER-Based Study. Adv Ther 36, 1211–1220 (2019). https://doi.org/10.1007/s12325-019-00918-5

Download citation

Keywords

  • Ovarian cancer
  • Survival
  • Thyroid cancer
  • TSH suppression therapy